DRUG
Terlipressin
Terlipressin (20-100 mcg/hr) plus norepinephrine and/or epinephrine
Status
Unknown
Phase
Phase 2
Enrollment
130
Locations
1
Results
Not posted
Publications
3
Study summary
Norepinephrine was recommended as the first vasopressor for septic shock resuscitation. For the patient who did not response to high dose norepinephrine, epinephrine was recommended. Vasopressin was also recommended as an alternative vasopressor, in case patient did not response to norepinephrine and or epinephrine. Terlipressin, a selective V1 receptor binding with long half life, was reported that it main action is to increase blood pressure via the different mechanism from norepinephrine and epinephrine. To use terlipressin, combine with norepinephrine and or epinephrine among refractory septic shock, could decrease the usage dose of norepinephrine and epinephrine as well as lower the side effects of too high adrenergic stimuli.
Norepinephrine was recommended as the first vasopressor for septic shock resuscitation. For the patient who did not response to high dose norepinephrine, epinephrine was recommended. Both norepinephrine and epinephrine action via the alpha adrenergic stimuli to increase vascular smooth muscle contraction, induced vasoconstriction and increase arterial blood pressure. It also action via beta adrenergic stimuli, to increase heart rate and myocardial contractility, then increase stroke volume and cardiac output. Too much alpha and beta adrenergic stimulation, especially during received high dose norepinephrine and or epinephrine associated with vasoconstriction induce organs ischemia. The most common organ ischemia included myocardial ischemia, bowel ischemia and limbs ischemia. Cardiac arrhythmia was also the most common complication associated with high dose norepinephrine and or epinephrine. Atrial fibrillation was the most common reported arrhythmia, however, fatal arrhythmia included ventricular fibrillation and tachycardia were also reported. Vasopressin was recommended as an alternative vasopressor, in case patient did not response to norepinephrine and or epinephrine. Terlipressin, a selective V1 receptor binding with long half life, was reported that it main action is to increase blood pressure via the different mechanism from norepinephrine and epinephrine. To use terlipressin, combine with norepinephrine and or epinephrine among refractory septic shock, could decrease the usage dose of norepinephrine and epinephrine as well as lower the side effects of too high adrenergic stimuli. The benefit effect of terlipressin could be demonstrated when prescribe among the septic shock patients who required high dose of adrenergic vasoactive agents. Terlipressin plus norepinephrine and or epinephrine could maintain or even improve blood pressure and tissue perfusion with lower fatal side effects than norepinephrine and or epinephrine without terlipressin.
Interventions
DRUG
Terlipressin (20-100 mcg/hr) plus norepinephrine and/or epinephrine
DRUG
0.9% NaCl plus norepinephrine and/or epinephrine
Timeline
First posted
Apr 9, 2020
Study start
Apr 3, 2020
Primary completion
Mar 31, 2025
Study completion
Jul 31, 2025
Results posted
Not reported
Registry updated
Sep 24, 2021
Outcomes
Achieve target blood pressure with low dose adrenergic agents
Time frame · 6 hours after initiate study drug
Achieve target mean arterial blood pressure 65 millimeter mercury or more with norepinephrine and/or epinephrine dose 0.2 mcg/kg/min or lower
28 day mortality
Time frame · 28 days
Proportion of patient who dead before 28 days after enrollment
Mean arterial blood pressure
Time frame · 72 hours
Mean arterial blood pressure after initiate study drug
Hospital mortality
Time frame · 90 days
Proportion of patient who dead before hospital discharge after enrollment
ICU mortality
Time frame · 90 days
Proportion of patient who dead before ICU discharge after enrollment
Eligibility
Inclusion Criteria: * Septic shock according to Sepsis-3 definition * Evidence of adequate fluid * Received norepinephrine 0.2 mcg/kg/min or more * Received norepinephrine plus epinephrine (any dose) * Mean arterial lower than 65 mmHg or lactate \> 2 mmol/liter Exclusion Criteria: 1. Septic shock diagnosis \> 48 hours before 2. Receive intravenous fluid \< 30 mL/kg before enrollment 3. Do-not-resuscitation and terminally ill 4. Refractory to treatment malignancy 5. Pregnancy 7\. Chronic renal failure stage 5 with no plan for long term renal replacement therapy 8. Cirrhosis child C 9. Cardiogenic shock 10. Acute decompensated heart failure 11. Evidence of left ventricular ejection fraction (LVEF) \< 35% 12. Acute coronary syndrome within 72 hours 13. Severe valvular heart disease 14. Documented life-threatening tachyarrhythmia before enrollment 15. Diagnosis of acute mesenteric ischemia before enrollment 16. Previous diagnosis of Raynaud's phenomenon 17. Known peripheral arterial disease 18. Refuse to sign the informed consent by patient or representative
Study locations
Thailand. Showing up to 24 locations stored in the fast local snapshot.
Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University
Bangkok, Thailand
Publications
Related trials
First Affiliated Hospital, Sun Yat-Sen University · Liver Neoplasms · Postoperative Complications
Not applicable
Completed
161
2026-07
Dayanand Medical College and Hospital · Alcoholic Hepatitis
Phase 3
Active, not recruiting
174
2026-07
Beijing Friendship Hospital · Kidney Transplant · Delayed Graft Function
Not applicable
Active, not recruiting
150
2026-07
University Hospital, Rouen · Bronchial Endoscopy
Phase 3
Completed
130
2026-06
Istanbul Medipol University Hospital · Liver Transplantation · Portal Hypertension
Not applicable
Recruiting
50
2026-04
Assistance Publique - Hôpitaux de Paris · Hemoptysis
Phase 3
Completed
315
2026-04
Noorik Biopharmaceuticals AG · Hepatorenal Syndrome · Liver Cirrhosis
Phase 2
Active, not recruiting
54
2026-04
Institute of Liver and Biliary Sciences, India · Acute-on-Chronic Liver Failure (ACLF)
Not applicable
Not yet recruiting
56
2026-03
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.